Content about Pharmaceutics

October 4, 2011

A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

NEW YORK — A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

The Wall Street Journal reported that the Mumbai-based company planned to launch 25 to 30 new generic drugs each year over the next couple of years.

October 4, 2011

Taro Pharmaceutical Industries recently appointed a new member to its board, following the resignation of Hasmukh Shah.

HAWTHORNE, N.Y. — Taro Pharmaceutical Industries recently appointed a new member to its board, following the resignation of Hasmukh Shah.

Shah, who cited personal reasons for leaving the drug maker's board, was replaced by Dov Pekelman, who currently serves as chairman of both Atera Networks and Gilon Investments. Pekelman also served as senior consultant for Teva Pharmaceutical Industries from 1985 to 2008.

Pekelman will serve until Taro's next annual general meeting of shareholders.

October 4, 2011

The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.

PARSIPPANY, N.J. — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.

The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.

September 30, 2011

Drug maker Takeda has completed its acquisition of another drug maker.

OSAKA, Japan — Drug maker Takeda has completed its acquisition of another drug maker.

Takeda said that the deal, valued at $13 billion, is in line with the company's 2011-2013 mid-range plan, and that Nycomed's significant business infrastructure in Europe and high-growth emerging markets will enhance Takeda's regulatory development expertise and commercialization capability.

September 22, 2011

Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

NEW YORK — Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

Dr. Reddy's announced the launch of rivastigmine tartrate capsules in the 1.5-mg, 3-mg, 4.5-mg and 6-mg strengths.

The drug is a generic version of Novartis' Exelon. Exelon and other generic versions of the drug had sales of about $92.6 million during the 12-month period ended in June, according to IMS Health.

September 21, 2011

Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

PITTSBURGH — Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

Mylan announced Wednesday that it had entered a settlement and license agreement with Hoffmann La Roche resolving a patent infringement lawsuit over Xeloda (capecitabine) tablets, a drug used to treat breast and colorectal cancers that have spread to other parts of the body.

September 16, 2011

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 15, 2011

Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

LANGHORNE, Pa. — Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

September 13, 2011

GlaxoSmithKline's Consumer Healthcare division has appointed a former Kraft Foods executive as its new chief customer officer.

PITTSBURGH — GlaxoSmithKline's Consumer Healthcare division has appointed a former Kraft Foods executive as its new chief customer officer.

In his new role, Keith Loranger will be responsible for leading the GSK Consumer Healthcare’s sales function to increase sales and profit for the company’s oral health and wellness categories, including such brands as Aquafresh, NicoDerm CQ and Tums, among others. Prior to joining the company, Loranger served as Kraft Foods' customer VP international strategy after joining the company in 1985.

September 13, 2011

Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

HAYWARD, Calif. — Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

September 12, 2011

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone.

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone. As patents on these blockbuster drugs have expired, they’ve provided generic manufacturers with enormous revenues, helping some to join the ranks of the world’s biggest drug companies.


September 12, 2011

The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


September 12, 2011

Genentech has applied for Food and Drug Administration approval of a drug for treating skin cancer, the drug maker said Monday.

SOUTH SAN FRANCISCO, Calif. — Genentech has applied for Food and Drug Administration approval of a drug for treating skin cancer, the drug maker said Monday.

Genentech, the U.S. division of Swiss drug maker Roche, submitted a new drug application to the FDA for vismodegib for the treatment of basal cell carcinoma. BCC generally is curable through surgery, but if it advances, can cause disfigurement and debilitating effects and, in the long term, can be life-threatening.

September 12, 2011

While settlements constitute the most prominent patent-related issue for generic drugs, two others have cropped up this year as well.


NEW YORK — While settlements constitute the most prominent patent-related issue for generic drugs, two others have cropped up this year as well.


September 12, 2011

At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


September 12, 2011

The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO.

EXECUTIVE NEWS — The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO. Neas, currently president and CEO of the National Coalition on Health Care, replaces Kathleen Jaeger, who stepped down as president and CEO of GPhA in May 2010 after eight years with the organization. The GPhA said it planned to spend September introducing Neas to stakeholders in a broad outreach effort.


September 9, 2011

The Food and Drug Administration has approved a generic drug made by Mylan for treating allergies.

PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for treating allergies.

Mylan announced Friday the approval of promethazine hydrochloride tablets in the 12.5-mg, 25-mg and 50-mg strengths.

Promethazine hydrochloride tablets, which are manufactured by several companies, had sales of about $42 million during the 12-month period ended in June, according to IMS Health.

September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

September 8, 2011

Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.

NEW YORK — Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.

Bristol said it has completed the acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals, based in San Diego, for $325 million. Amira's portfolio focuses on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

The transaction was originally announced on July 21.

September 8, 2011

Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

NEW YORK — Ranbaxy Labs will launch its generic version of the world's top-selling drug as originally planned, according to published reports.

Citing Japan's Nikkei daily, Reuters reported that Gurgaon, India-based Ranbaxy would launch a generic version of Pfizer's cholesterol medication Lipitor (atorvastatin) at the end of November.

September 8, 2011

Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker's life science division.

DARMSTADT, Germany — Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker's life science division.

Yates will report to Bernd Reckmann, who leads the company's chemicals business sector, which includes the Merck Millipore and performance materials division. Millipore was acquired by Merck in July 2010.

Prior to his new role, Yates worked at Roche for 22 years, most recently in Roche's diagnostics division, where he led the life sciences business in Penzberg, Germany.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

September 1, 2011

Branded drugs sold under their generic names at a reduced price can reduce retail and wholesale drug prices, according to a new report by the Federal Trade Commission.

WASHINGTON — Branded drugs sold under their generic names at a reduced price can reduce retail and wholesale drug prices, according to a new report by the Federal Trade Commission.

The FTC report found that when an authorized generic is introduced onto the market, it can lower the expected profits of the generic drug's manufacturer and, over the longer term, affect generic manufacturers' decisions to challenge patents covering branded drugs with low sales, though patent challenges by generic drug makers "remain robust."

September 1, 2011

GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

PITTSBURGH — GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

“Clark has been a valuable team member throughout his many years with GSK, and his passion and effective leadership of the U.S. consumer sales team has been critical to the success of our business,” stated Colin Mackenzie, president GSK Consumer Healthcare North America.

August 30, 2011

Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.

Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.